MicroRNAs From Blood Samples as Biomarkers for Gastric Cancer Detection
NCT ID: NCT05901376
Last Updated: 2023-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
280 participants
OBSERVATIONAL
2023-04-25
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is:
\- Can microRNAs be effectively used as diagnostic biomarkers for gastric cancer?
Participants will be asked for their consent to obtain 5 cc of blood.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
NCT06776835
Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer
NCT03076567
Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
NCT05269056
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
NCT07224750
Use of Circulating Exosomal LncRNA-GC1 to Monitor Gastric Cancer
NCT05397548
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gastric Cancer
MicroRNA
MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
Control
MicroRNA
MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MicroRNA
MiR-20a, MiR-21, MiR-106b, MiR-199a, MiR-223
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Never received any treatment for gastric cancer
* Age 50 or above
* Underwent elective upper gastrointestinal endoscopy and negative for gastric cancer
* No prior history of gastric dysplasia or cancer
Exclusion Criteria
* Pregnancy
* Lymphoma
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Chulalongkorn Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rapat Pittayanon
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Chulalongkorn Memorial Hospital
Bangkok, Not Required For This Country, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RP023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.